Vicore Announces Presentations at the European Respiratory Society Congress 2025

STOCKHOLM, SE / ACCESS Newswire / September 23, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the European Respiratory Society (ERS) Congress 2025, taking place in Amsterdam, the Netherlands, from September 27 - October 1, 2025.

Vicore will present new findings from the 36-week Phase 2a AIR trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), including a synthetic control arm (SCA) analysis. This analysis, using SCAs generated from a real-world database of over 10,000 IPF patients, strongly supports buloxibutid's beneficial treatment effect. Among patients with comparable baseline characteristics, buloxibutid showed statistically significant improvement in forced vital capacity (FVC) at 36 weeks relative to both baseline and synthetic control, confirming the disease-modifying signal observed in the AIR trial.

Vicore will also share data on Almee, a digital cognitive behavioral therapy in development, demonstrating its impact on general life satisfaction and quality of life in patients with pulmonary fibrosis in the United States.

Oral Presentations

• The novel angiotensin II type 2 receptor agonist buloxibutid improves lung function in IPF compared to real-world external IPF control arms (OA1249)
  Session 108: Emerging clinical trials in pulmonary fibrosis
  Date: Sunday, September 28, 2025
  Presentation Time: 11:00 AM CEST
  Location: Elicium 1

• Effects on life satisfaction using a digital therapy in individuals with pulmonary fibrosis - randomised controlled investigation (OA2347)
  Session 202: Shaping the future of respiratory care through artificial intelligence and evidence-based digital strategies
  Date: Sunday, September 28, 2025
  Presentation Time: 4:05 PM CEST
  Location: 3B

Late-Breaking Poster Presentation

• Synthetic arm generation utilizing real-world patient data demonstrates treatment effect in the Phase 2a AIR trial of buloxibutid in IPF (PA3043)
  Session 246: Alveolar filling disorders and autoimmune lung diseases
  Date: Monday, September 29, 2025
  Poster Session Time: 8:00 - 9:30 AM CEST
  Location: PS-37

Following the presentations, the poster will be available on the Publications page of Vicore's website.

For further information, please contact: